Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURI: Empagliflozin in Cardiac Surgery
NCT06825156Phase 4Completed
- Sponsor
- University of Amsterdam
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin in acute kidney injury (AKI) (2 arms), sponsored by University of Amsterdam. Primary endpoint: Neutrophil Gelatinase-Associated Lipocalin. Started Mar 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06825156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825156.